AMLprofiler publications

Key publication for the AMLprofiler

Valk, P.J.M. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004). Link

Scientific Background References

1.      Döhner, H. et al. Diagnosis and management of acute myeloid leukemia in adults:  recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474 (2010). Link

2.      Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937 -951 (2009). Link

3.      Mrózek, K. & Bloomfield, C.D. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J. Natl. Cancer Inst. Monographs 52-57 (2008).doi:10.1093/jncimonographs/lgn003 Link

4.      Löwenberg, B. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction. N. Engl. J. Med. 358, 1960-1962 (2008). Link

5.      Marcucci, G., Mrózek, K. & Bloomfield, C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr. Opin. Hematol. 12, 68-75 (2005). Link

6.      Bienz, M. et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin. Cancer Res. 11, 1416-1424 (2005). Link

7.      Wouters, B.J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113, 3088-3091 (2009). Link

8.      Schlenk, R.F. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-1918 (2008).  Link

9.      Figueroa, M.E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010). Link

10.   Suzuki, T. et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106, 2854-2861 (2005). Link

11     .Döhner, K. et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106, 3740-3746 (2005). Link

12     .Verhaak, R.G.W. et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106, 3747-3754 (2005). Link

13.   Gale, R.E. et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111, 2776-2784 (2008). Link

14.   Schnittger, S. et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106, 3733-3739 (2005). Link

15.   Lugthart, S. et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111, 4329-4337 (2008). Link

16.   Barjesteh van Waalwijk van Doorn-Khosrovani, S. et al. High EVI1 expression predicts poor  survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101, 837-845 (2003).  Link

17.   Gröschel, S. et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J. Clin. Oncol. 28, 2101-2107 (2010). Link

18.   Baldus, C.D. et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J. Clin. Oncol. 24, 790-797 (2006). Link

19.   Baldus, C.D. et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102, 1613-1618 (2003). Link

20.   Santamaría, C. et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann. Hematol. 89, 453-458 (2010). Link

21.   Langer, C. et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111, 5371-5379 (2008). Link